The global platelet aggregation devices market is poised to reach ~$342.4 Million by 2020, growing at a CAGR of 21.0% from 2015 to 2020. Market growth can be attributed to factors such as rising incidence of target diseases, rapid growth in the geriatric population across the globe, technological advancements in platelet aggregometers, and increasing number of industry-academia collaborations & clinical studies. However, factors such as procedural limitations, unfavorable healthcare reforms in the U.S., and dearth of well trained & skilled professionals are restraining the growth of this market. In addition, stringent regulatory policies and limited medical reimbursements are posing significant challenges for the growth of the market.

On the basis of product, the global platelet aggregation devices market is classified into three major segments, namely, instruments, reagents, and consumables & accessories. The Systems segment is expected to account for the largest share of the global market in 2015. This product segment is expected to grow at the highest CAGR in the next five years, owing to factors such as continuous technological advancements in the field of sensors and detectors, rising trend of automation of platelet aggregation testing procedures, growing adoption & market preference for automated instruments among diagnostic laboratories, and improved patient compliance offered by point-of-care testing analyzers as compared to conventional instruments.

On the basis of end user, the global platelet aggregation devices market is classified into standalone hospitals, diagnostic laboratories, research & academic institutes, and other end users (blood banks & pharmaceutical-biotechnology companies).Standalone hospitals segment is expected to account for the largest share of the global market in 2015. This segment is expected to grow at the highest CAGR in the next five years as well, owing to benefits offered by hospitals in conducting platelet aggregation testing procedure, large patient population base for target diseases (such as bleeding disorders, cardiovascular diseases, and arthritis), growing public-private investments for development and modernization of healthcare infrastructure, and increasing number of hospitals across developing countries.

Geographically, the platelet aggregation devices market is classified into four regions, namely, North America, Europe, Asia-Pacific, and the Rest of the World. In 2015, the global market is expected to be dominated by North America. North American platelet aggregation devices market is also poised to grow at the highest CAGR owing to factors such as large patient population for target diseases (such as arthritis, leukemia, and hemophilia), strong presence of device manufacturers in the region, growing number of surgical procedures performed annually, growing awareness among healthcare professionals (related to the benefits offered by platelet aggregation testing in disease diagnosis), and availability of significant investments to support R&D programs that utilize platelet

New product launches and product developments are the key strategies adopted by major players to develop their positions in the global platelet aggregation devices market. Moreover, strategies such as acquisitions & divestments; partnerships, agreements, & collaborations; and geographic expansions were also adopted by a significant number of market players to strengthen their product portfolios and to expand their geographic presence in the global market. F. Hoffmann La-Roche Ltd. (Switzerland), Haemonetics Corporation (U.S.), Sysmex Corporation (Japan), Siemens AG (Germany), Accriva Diagnostics (U.S.), Helena Laboratories Corporation (U.S.), Bio/Data Corporation (U.S.), Tem Group (Switzerland), Sentinel CH. S.p.A. (Italy), and Aggredyne, Inc. (U.S.) are the key players operating in the global Platelet Aggregation Devices Market.